Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00132158
Status:
COMPLETED
Last Update Posted:
2012-04-17
First Post:
2005-08-17
Brief Title:
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
Sponsor:
St Jude Childrens Research Hospital
Organization:
St Jude Childrens Research Hospital
Study Overview
Official Title:
A Dose Finding Study Phase I of the Combination of ZD1839 Iressa and an Oral Formulation of Irinotecan Camptosar in Children With Refractory Solid Tumors
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this Phase I study is to find the largest dose of the drug irinotecan in combination with ZD1839 that can be given safely to children and to learn the good and bad effects Studies performed in the laboratory have shown that ZD1839 helps make available the orally administered irinotecan In this study the intravenous given into the vein formula of irinotecan will be given orally on days 1-5 and days 8-12 The dose of ZD1839 will be a fixed dose and will be administered orally on days 1-12 Each course of treatment will consist of 21 days The administration of irinotecan on day 12 of course 1 and day 2 of course 2 will be an intravenous administration All other doses and subsequent courses will consist of an orally administered dose
Detailed Description:
This is a phase I study to estimate the maximum tolerated dose and the dose limiting toxicities of the intravenous formulation of irinotecan given orally in combination with a fixed dose of oral gefitinib This trial will use the EWOC method which is an adaptive dose escalation scheme The method is fully adaptive and makes use of all the information available at the time of each dose assignment and directly addresses the ethical need to control the probability of overdosing It is designed to approach the maximum tolerated dose MTD as fast as possible
In this study the intravenous formulation of irinotecan will be given orally on days 1-5 and days 8-12 dose level begins at 5 mgm2 One patient will be treated at each dose level of irinotecan until moderate toxicity is observed At the level where moderate toxicity is observed the cohort size will be increased to 2 patients Dosages will then be increased until the development of DLT as guided by the EWOC model The estimated MTD will be continually reassessed using all data from preceding patients The toxicity data of all patients enrolled in the trial are used to update the dose-toxicity relationship and to guide the next escalationde-escalation The calculation will be carried out with EWOC software Patients will be enrolled and the dose assigned is determined based on previous participants toxicity The dose of ZD1839 will be a fixed dose and will be administered orally on days 1-12 - 150 mgm2 maximum 250 mg Each course of treatment will consist of 21 days The administration of irinotecan on day 12 of course 1 and day 2 of course 2 will be an intravenous administration All other doses and subsequent courses will consist of an orally administered dose
Secondary Objectives Include
To describe dose-limiting toxicities DLTs of the combination of oral irinotecan and ZD1839 and to define their duration and reversibility
To investigate the pharmacokinetics of oral irinotecan and ZD1839 when given in combination in children with recurrent malignant solid tumors
To describe the relationship between pharmacokinetic parameters and toxicity
To describe any antitumor effects within the confines of a phase I study
To examine tumor expression of ErbB1 andor ABCG2 with respect to pharmacokinetics and response
To examine the pharmacogenetic determinants of ZD1839 and irinotecan pharmacokinetics and pharmacodynamics
In this study the intravenous formulation of irinotecan will be given orally on days 1-5 and days 8-12 dose level begins at 5 mgm2 One patient will be treated at each dose level of irinotecan until moderate toxicity is observed At the level where moderate toxicity is observed the cohort size will be increased to 2 patients Dosages will then be increased until the development of DLT as guided by the EWOC model The estimated MTD will be continually reassessed using all data from preceding patients The toxicity data of all patients enrolled in the trial are used to update the dose-toxicity relationship and to guide the next escalationde-escalation The calculation will be carried out with EWOC software Patients will be enrolled and the dose assigned is determined based on previous participants toxicity The dose of ZD1839 will be a fixed dose and will be administered orally on days 1-12 - 150 mgm2 maximum 250 mg Each course of treatment will consist of 21 days The administration of irinotecan on day 12 of course 1 and day 2 of course 2 will be an intravenous administration All other doses and subsequent courses will consist of an orally administered dose
Secondary Objectives Include
To describe dose-limiting toxicities DLTs of the combination of oral irinotecan and ZD1839 and to define their duration and reversibility
To investigate the pharmacokinetics of oral irinotecan and ZD1839 when given in combination in children with recurrent malignant solid tumors
To describe the relationship between pharmacokinetic parameters and toxicity
To describe any antitumor effects within the confines of a phase I study
To examine tumor expression of ErbB1 andor ABCG2 with respect to pharmacokinetics and response
To examine the pharmacogenetic determinants of ZD1839 and irinotecan pharmacokinetics and pharmacodynamics
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IRUSIRES0181 | OTHER | AstraZeneca | None |